Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation

Cancer Investigation

Volumn 26, Issue 8, 2008, Pages 784-793

  Fountzilas, George ^a   Bobos, Mattheos ^a   Kalogera Fountzila, Anna ^a   Xiros, Nikolaos ^b   Murray, Samuel ^c   Linardou, Helena ^c   Karayannopoulou, Georgia ^a   Koutras, Angelos K ^d   Bafaloukos, Dimitrios ^c   Samantas, Epaminondas ^e   Christodoulou, Christos ^f   Economopoulos, Theofanis ^b   Kalogeras, Konstantine T ^a,g   Kosmidis, Paris ^h  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f HENRY DUNANT HOSPITAL   (Greece)

^g Hellenic Cooperative Oncology Group   (Greece)

^h HYGEIA HOSPITAL   (Greece)

Author keywords

Chemotherapy; Gefitinib; Gemcitabine; Pancreatic cancer

Indexed keywords

GEFITINIB; GEMCITABINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; GENE DELETION; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUTATIONAL ANALYSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SALIVARY GLAND DISEASE; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENES, ERBB-2; GENES, RAS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 53949121341     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801918611     Document Type: Article

References (41)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M.J. Cancer statistics, 2006. CA Cancer J Clin 2006, 56, 106-130.
2. Sultana, A.; Smith, C.T.; Cunningham, D.; Starling, N.; Neoptolemos, J.P.; Ghaneh, P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007, 25, 2607-2615.
3. Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W.L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslypse, C.; Neumann, H.; Safran, H.; Humblet, Y.; Perez Ruixo, J.; Ma, Y.; Von Hoff, D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004, 22, 1430-1438.
4. Louvet, C.; Labianca, R.; Hammel, P.; Liedo, G.; Zampino, M.G.; Andre, T.; Zaniboni, A.; Ducreux, M.; Aitini, E.; Taieb, J.; Faroux, R.; Lepere, C.; de Gramont, A.; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15), 3509-3516.
5. Hochster, H.S.; Haller, D.G.; de Gramont, A.; Berlin, J.D.; Philip, P.A.; Moore, M.J.; Ajani, J.A. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006, 107(4), 676-685.
6. Xie, D.R.; Liang, H.L.; Wang, Y.; Guo, S.S.; Yang, Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006, 12(43), 6973-81.
7. Overholser, J.P.; Prewett, M.C.; Hooper, A.T.; Waksal, H.W.; Hicklin, D.J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89(1), 74-82.
8. Yamanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Beger, H.G.; Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993, 3(3), 565-569.
9. Bruns, C.J.; Solorzano, C.C.; Harbison, M.T.; Ozawa, S.; Tsan, R.; Fan, D.; Abbruzzese, J.; Traxler, P.; Buchdunger, E.; Radinsky, R.; Fidler, I.J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60(11), 2926-2935.
10. Bruns, C.J.; Harbison, M.T.; Davis, D.W.; Portera, C.A.; Tsan, R.; McConkey D.J.; Evans, D.B.; Abbruzzese, J.L.; Hicklin, D.J.; Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000, 6(5), 1936-1948.
11. Li, J.; Kleeff, J.; Giese, N.; Buchler, M.W.; Korc, M.; Friess, H. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 2004, 25(1), 203-210.
12. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3), 205-216.
13. Ajani, J.A.; Welch, S.R.; Raber, M.N.; Fields, W.S.; Krakoff, I.H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990, 8(2), 147-59.
14. Pallares, J.; Bussaglia, E.; Martinez-Guitarte, J.L.; Dolcet, X.; Llobet. D.; Rue, M.; Sanchez-Verde, L.; Palacios, J.; Prat, J.; Matias-Guiu, X. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Modern Pathol 2005, 18, 719-727.
15. Italiano, A.; Saint-Paul, M.C.; Caroli-Bosc, F.X.; Francois, E.; Bourgeon, A.; Benchimol, D.; Gugenheim, J.; Michiels, J.F. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 2005, 16, 1503-1507.
16. Choe, G.; Horvath, S.; Cloughesy, T.F.; Crosby, K.; Seligson, D.; Palotie, A.; Inge, L.; Smith, B.L.; Sawyers, C.L.; Mischel. P.S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003, 63, 2742-2746.
17. Perren, A.; Weng, L.P.; Boag, A.H.; et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155, 1253-1260.
18. Fountzilas, G.; Karkavelas, G.; Kalogera-Fountzila, A.; Karina, M.; Ignatiadis, M.; Koukoulis, G.; Plataniotis, G.; Misailidou, D.; Bobos, M.; Pectasides, D.; Razis, E.; Karavelis, A.; Selviaridis, P. Postoperative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res 2006, 26, 4675-4686.
19. Sunpaweravong, P.; Sunpaweravong, S.; Puttawibul, P.; Mitarnun, W.; Zeng, C.; Baron, A.E.; Franklin, W.; Said, S.; Varella-Garcia, M. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005, 131, 111-119.
20. Murray, S.; Timotheadou, E.; Linardou, H.; Vrettou, A.V.; Kostopoulos, I.; Skrickova, J.; Papakostantinou, C.; Christodoulou, C.; Pectasides, D.; Samantas, E.; Papakostas, P.; Skarlos, D.V.; Kosmidis, P.; Fountzilas, G. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006, 52, 225-233.
21. Travis, W.D.; Colby, T.V.; Corrin, B.; Shimosato, Y.; Brambilla, E. Histological typing of lung and pleural tumors, 3rd edition, Springer Verlag: Berlin, 1999.
22. Pao, W.; Wang, TY.; Riely, G.J.; Miller, V.A.; Pan, Q.; Ladanyi, M.; Zakowski, M.F.; Heelan, R.T.; Kris, M.G.; Varmus, H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2, 57-61.
23. Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25, 1960-1966.
24. Shadad, F. Phase II study of gefitinib and docetaxel as salvage therapy in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 2006, 24, (Suppl 18), (Abstr 4120).
25. Cascinu, S.; Berardi, R.; Siena, S.; La bianca, R.; Falcone, A.; Aitini, E.; Barni, S.; Di Costanzo, F.; Frontini, L.; Tonini, G.; Zaniboni, A. The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD. J Clin Oncol 2007, 25, (Suppl 18), (Abstr 4544).
26. Abou-Alfa, G.K.; Letourneau, R.; Harker, G.; Modiano, M.; Hurwitz, H.; Tchekmedyian, N.S.; Feit, K.; Ackerman, J.; De Jager, R.L.; Eckhardt, S.G.; O'Reilly, E.M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24(27), 4441-4447.
27. Perez-Soler, R.; Delord, J.P.; Halpern, A.; Kelly, K.; Krueger, J.; Sureda, B.M.; von Pawel, J.; Temel, J.; Siena, S.; Soulieres, D.; Saltz, L.; Leyden, J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10(5), 345-356. Review.
28. Lynch, T.J. Jr; Kim, E.S.; Eaby, B.; Garey, J.; West, D.P.; Lacouture, M.E. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007, 12, 610-621.
29. El-Rayes, B.F.; Ali, S.; Ali, I.F.; Philip, P.A.; Abbruzzese, J.; Sarkar, F.H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res 2006, 66, 10553-10559.
30. Safran, H.; Steinhoff, M.; Mangray, S.; Rathore, R.; King, T.C.; Chai, L.; Berzein, K.; Moore, T.; Iannitti, D.; Reiss, P.; Pasquariello, T.; Akerman, P.; Quirk, D.; Mass, R.; Goldstein, L.; Tantravahi, U. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001, 24(5), 496-499.
31. Fernandez, M.; Eng, C. The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary. Clin Cancer Res 2002, 8(6), 1695-1698.
32. Ohgaki, H.; Kleihues, P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170, 1445-1453.
33. Hayes, M.P.; Wang, H.; Espinal-Witter, R.; Douglas, W.; Solomon, G.J.; Baker, S.J.; Ellenson, L.H. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006, 12, 5932-5935.
34. Asano, T.; Yao, Y.; Zhu, J.; Li, D.; Abbruzzese, J.L.; Reddy, S.A.G. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23, 8571-8580.
35. She, Q.B.; Solit, D.; Basso, A.; Moasser, M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003, 9, 4340-4346.
36. Haas-Kogan, D.A.; Prados, M.D.; Tihan, T.; Eberhard, D.A.; Jelluma, N.; Arvold, N.D.; Baumber, R.; Lamborn, K.R.; Kapadia, A.; Malec, M.; Berger, M.S.; Stokoe, D.J. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. Natl Cancer Inst 2005, 97(12), 880-887.
37. Yano, S.; Matsuyama, H.; Hirata, H.; Inoue, R.; Matsumoto, H.; Ohmi, C.; Miura, K.; Shirai, M.; Iizuka, N.; Naito, K. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep 2006, 15(6), 1453-1460.
38. Han, S.W.; Kim, T.Y.; Jeon, Y.K.; Hwang, P.G.; Im, S.A.; Lee, K.H.; Kim, J.H.; Kim, D.W.; Heo, D.S.; Kim, N.K.; Chung, D.H.; Bang, Y.J. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12, 2538-2544.
39. Kwak, E.L.; Jankowski, J.; Thayer, S.P.; Lauwers, G.Y.; Brannigan, B.W.; Harris, P.L.; Okimoto, R.A.; Haserlat, S.M.; Driscoll, D.R.; Ferry, D.; Muir, B.; Settleman, J.; Fuchs, C.S.; Kulke, M.H.; Ryan, D.P.; Clark, J.W.; Sgroi, D.C.; Haber, D.A.; Bell, D.W. Epidermal growth factor receptor kinase domain mutation in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006, 12, 4283-4287.
40. Lee, J.; Jang, K.T.; Ki, C.S.; Lim, T.; Park, Y.S.; Lim, H.Y.; Choi, D.W.; Kang, W.K.; Park, K.; Park, J.O. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007, 109, 1561-1569.
41. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.